KeyBanc last night initiated coverage of Hims & Hers with a Sector Weight rating and no price target The firm views Hims as a “disruptive” direct-to-consumer healthcare business. It is “intrigued” by the company’s international ramp and expansion into more treatments, but believes it may lead to “more muted” margin expansion in 2026. KeyBanc’s fair value estimate is $52 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS: